Cytokinetics (CYTK) Cash from Investing Activities (2010 - 2026)

Cytokinetics (CYTK) has reported Cash from Investing Activities for 17 consecutive years, with $145.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 37.31% year-over-year to $145.5 million; the TTM figure through Mar 2026 stood at $56.2 million (up 111.71% YoY), while the FY2025 annual figure was $16.7 million, up 103.01% from the prior year.
• Cash from Investing Activities climbed to $145.5 million in Q1 2026 per CYTK's latest filing, from -$71.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $165.5 million in Q1 2023 and bottomed at -$651.5 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$24.3 million across 5 years, with a median of $32.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1118.33% — and 2023, when it soared 357.47%.
• Cytokinetics' Cash from Investing Activities stood at $29.2 million in 2022, then sank by 378.34% to -$81.4 million in 2023, then jumped by 236.18% to $110.9 million in 2024, then slumped by 164.22% to -$71.2 million in 2025, then jumped by 304.37% to $145.5 million in 2026.
• Business Quant data shows CYTK's Cash from Investing Activities at $145.5 million in Q1 2026, -$71.2 million in Q4 2025, and -$71.0 million in Q3 2025.